Combining 90Y-ibritumomab Tiuxetan With High-dose Chemotherapy of BuCyE and Autologous Stem Cell Transplantation in Patients With B-cell Non-Hodgkin's Lymphoma - an Open-labeled Phase II Study
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2016
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Busulfan; Cyclophosphamide; Etoposide
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 07 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Inclusion criteria amended from NCT
- 12 May 2009 Planned end date changed from 1 Dec 2008 to 1 Aug 2010 as reported by ClinicalTrials.gov.